Drug repurposing and adverse event prediction using high-throughput literature analysis

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 3, Issue 3, 2011, Pages 323-334

  Deftereos, Spyros N ^a   Andronis, Christos ^a   Friedla, Ellen J ^a   Persidis, Aris ^a   Persidis, Andreas ^a  

^a Biovista Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ANIMAL; BIOLOGICAL MODEL; DRUG DEVELOPMENT; DRUG REPOSITIONING; HUMAN; REVIEW;

ANIMALS; DRUG DISCOVERY; DRUG REPOSITIONING; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS;

ANIMALIA;

EID: 79960304811     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.147     Document Type: Review

References (88)

1. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 2006, 25:420-428.
2. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003, 22:151-185.
3. Boguski MS, Mandl KD, Sukhatme VP. Drug discovery. Repurposing with a difference. Science 2009, 324:1394-1395.
4. Grabowski H. Are the economics of pharmaceutical research and development changing? Productivity, patents and political pressures. Pharmacoeconomics 2004, 22(2 suppl 2):15-24.
5. Wadman M. Experts call for active surveillance of drug safety. Nature 2007, 446:358-359.
6. Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007, 167:1752-1759.
7. Gilbert J, Henske P, Singh A. Rebuilding Big Pharma's Business Model. In Vivo, the Business & Medicine Report, Windhover Information, vol. 21; 2003.
8. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004, 3:673-683.
9. Carley DW. Drug repurposing: identify, develop and commercialize new uses for existing or abandoned drugs. Part II. Drugs 2005, 8:310-313.
10. PricewaterhouseCoopers. Pharma 2005 silicon rally: the race to e-R&D. Paraxel's Pharmaceutical R&D Statistical Sourcebook 2002/2003.
11. Netterwald J. Recycling existing drugs. Drug Disc Dev 2008, 16-22.
12. Frijters R, van Vugt M, Smeets R, van Schaik R, de Vlieg J, Alkema W. Literature mining for the discovery of hidden connections between drugs, genes and diseases. PLoS Comput Biol 2010, 6(9).
13. Jensen LJ, Saric J, Bork P. Literature mining for the biologist: from information retrieval to biological discovery. Nat Rev Genet 2006, 7: 119-129.
14. Persidis A, Deftereos S, Persidis A. Systems literature analysis. Pharmacogenomics 2004, 5943-947.
15. Deftereos S, Andronis C, Friedla EJ, Persidis A, Persidis A. Drug repurposing and adverse event prediction using high-throughput literature analysis: case studies. 8th International Conference on Pathways, Networks, and Systems Medicine, Rhodes July 9-14, 2010.
16. Kitano H. Systems biology: a brief overview. Science 2002, 295:1662.
17. Swanson DR. Complementary structures in disjoint science literatures. In: Bookstein A, Chiaramella Y, Salton G, Raghavan VV, eds. Proceedings of the 14th Annual International ACM/SIGIR Conference. New York: ACM Press; 1991, 280-289.
18. Swanson DR. Fish oil, Raynaud's syndrome, and undiscovered public knowledge. Perspect Biol Med 1986, 30:7-18.
19. Swanson DR. Migraine and magnesium: eleven neglected connections. Perspect Biol Med 1988, 31:526-557.
20. Vosgerau H. Migraine therapy with magnesium glutamate. Ther Ggw 1973, 112:640 passim.
21. Altura BM. Calcium antagonist properties of magnesium: implications for antimigraine actions. Magnesium 1985, 4:169-175.
22. Altura BM, Altura BT. New perspectives on the role of magnesium in the pathophysiology of the cardiovascular system. I. Clinical aspects. Magnesium 1985, 4:226-244.
23. DiGiacomo RA, Kremer JM, Shah DM. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study. Am J Med 1989, 86:158-164.
24. Schiapparelli P, Allais G, Castagnoli Gabellari I, Rolando S, Terzi MG, Benedetto C. Non-pharmacological approach to migraine prophylaxis: part II. Neurol Sci 2010, 31(suppl 1):S137-S139.
25. Smalheizer NR, Swanson DR. Linking estrogen to Alzheimer's disease: an informatics approach. Neurology 1996, 47:809-810.
26. Smalheizer NR, Swanson DR. Indomethacin and Alzheimer's disease. Neurology 1996, 46:583.
27. Smalheiser NR, Torvik VI. The place of literaturebased discovery in contemporary scientific practice. In: Weeber M, Bruza P, eds. Literature-based Discovery. Springer; Berlin 2008, 13-22.
28. Lindsay RK, Gordon MD. Literature-based discovery by lexical statistics.J Am Soc Inf Sci 1999, 50:574-587.
29. Gordon MD, Lindsay RK. Toward discovery support systems: A replication, re-examination, and extension of Swanson's work on literature-based discovery of a connection between Raynaud's and fish oil. J Am Soc Inf Sci 1996, 47:116-128.
30. Yetisgen-Yildiz M, Pratt W. Using statistical and knowledge-based approaches for literature-based discovery. J Biomed Inform 2006, 39:600-611.
31. Kostoff R. Validating discovery in literature-based discovery. J Biomed Inform 2007, 40:448-450.
32. Lindberg C. The Unified Medical Language System (UMLS) of the National Library of Medicine. J Am Med Rec Assoc 1990, 61:40-42.
33. Weeber M, Klein H, de Jong-van den Berg LTW, Vos R. Using concepts in literature based discovery: simulating Swanson's Raynaud-fish oil and migraine- magnesium examples. J Am Soc Inf Sci Technol 2001, 52:548-57.
34. Weeber M, Vos R, Klein H, De Jong-Van Den Berg LTW, Aronson AR, Molema G. Generating hypotheses by discovering implicit associations in the literature: a case report of a search for new potential therapeutic uses for thalidomide. J Am Med Inform Assoc 2003, 10:252-259.
35. Caseiro MM. Treatment of chronic hepatitis C in nonresponsive patients with pegylated interferon associated with ribavirin and thalidomide: report of six cases of total remission. Rev Inst Med Trop Sao Paulo 2006, 48:109-112.
36. Wren JD, Bekeredjian R, Stewart JA, Shohet RV, Garner HR. Knowledge discovery by automated identification and ranking of implicit relationships. Bioinformatics 2004, 20:389-398.
37. Thorazine (Chlorpromazine) drug information: uses, side effects, drug interactions and warnings at RxList. Available at: http://www.rxlist.com/thorazine-drug.htm. (Accessed October 7, 2010).
38. Hristovski D, Peterlin B, Mitchell JA, Humphrey SM. Improving literature based discovery support by genetic knowledge integration. Stud Health Technol Inf 2003, 95:68-73.
39. Ozgür A, Xiang Z, Radev DR, He Y. Literaturebased discovery of IFN- and vaccine-mediated gene interaction networks. J Biomed Biotechnol 2010, 2010:426-479.
40. Korbel JO, Doerks T, Jensen LJ, Perez-Iratxeta C, Kaczanowski S, Hooper SD, Andrade MA, Bork P. Systematic association of genes to phenotypes by genome and literature mining. PLoS Biol 2005, 3:e134.
41. Li J, Zhu X, Chen JY. Building disease-specific drugprotein connectivity maps from molecular interaction networks and PubMed abstracts. PLoS Comput Biol 2009, 5:e1000450.
42. Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 2005, 33:D514-D517.
43. Brown KR, Jurisica I. Online predicted human interaction database. Bioinformatics 2005, 21:2076-2082.
44. Hu Y, Hines LM, Weng H, Zuo D, Rivera M, Richardson A, LaBaer J. Analysis of genomic and proteomic data using advanced literature mining. J Proteome Res 2003, 2:405-412.
45. Loging W, Harland L, Williams-Jones B. Highthroughput electronic biology: mining information for drug discovery. Nat Rev Drug Discov 2007, 6:220-230.
46. Potts SJ, Edwards DJ, Hoffman R. Challenges of target/ compound data integration from disease to chemistry: a case study of dihydrofolate reductase inhibitors. Curr Drug Discov Technol 2005, 2:75-87.
47. Chemical Abstracts Service. Available at: www.cas.org/. (Accessed October 7, 2010).
48. Webb EC. Enzyme nomenclature 1992 recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the nomenclature and classification of enzymes. San Diego, CA: Published for the International Union of Biochemistry and Molecular Biology by Academic Press; 1992. ISBN 0-12-227164-5. Available at: http://www.chem.qmul.ac.uk/iubmb/enzyme/. (Accessed ctober 7, 2010).
49. Stegmann J, Grohmann G. Hypothesis generation guided by co-word clustering. Scientometrics 2003, 56:111-135.
50. Ingenuity. Available at: http://www.ingenuity.com/. (Accessed October 7, 2010).
51. GeneGo. Available at: http://www.genego.com/. (Accessed October 7, 2010).
52. Ariadne Genomics. Available at: http://www.ariadnegenomics.com/. (Accessed October 7, 2010).
53. Kotelnikova E, Yuryev A, Mazo I, Daraselia N. Computational approaches for drug repositioning and combination therapy design. J Bioinform Comput Biol, 8:593-606.
54. Biovista. Available at: http://www.biovista.com/. (Accessed October 7, 2010).
55. Deftereos SN, Andronis C, Virvillis V, Konstanti O, Persidis A. Dimebon ameliorates disease severity in the MOG-induced experimental allergic encephalomyelitis animal model of progressive multiple sclerosis. American Neurological Association 135th Annual Meeting, San Fransisco, September 12-15, 2010.
56. Deftereos SN, Andronis C, Sharma A, Aris Persidis A. Systematic drug repurposing for CNS indications: account of two successful case studies. American Neurological Association 135th Annual Meeting, San Fransisco, September 12-15, 2010.
57. Matthews EJ, Frid AA. Prediction of drug-related cardiac adverse effects in humans-A: creation of a database of effects and identification of factors affecting their occurrence. Regul Toxicol Pharmacol 2010, 56:247-275.
58. Adverse Event Reporting System (AERS). Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm. (Accessed October 7, 2010).
59. Thomson-Reuters-MicroMedex. Available at: http://www.micromedex.com/. (Accessed October 7, 2010).
60. Matthews EJ, Ursem CJ, Kruhlak NL, Benz RD, Sabaté DA, Yang C, Klopman G, Contrera JF. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: B. Use of QSAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities. Regul Toxicol Pharmacol 2009, 54:23-42.
61. Matthews EJ, Kruhlak NL, Benz RD, Sabaté DA, Marchant CA, Contrera JF. Identification of structure activity relationships for adverse effects of pharmaceuticals in humans: C. Use of QSAR and an expert system for the estimation of the mechanism of action of druginduced hepatobiliary and urinary tract toxicities. Regul Toxicol Pharmacol 2009, 54:43-65.
62. Ursem CJ, Matthews EJ, Kruhlak NL, Contrera JF, Benz RD. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans A: use of FDA post market reports to create a database of hepatobiliary and urinary tract toxicities. Regul Toxicol Pharmacol 2009, 54:1-22.
63. Harpaz R, Chase HS, Friedman C. Mining multiitem drug adverse effect associations in spontaneous reporting systems. BMC Bioinformatics 2010, 11(suppl 9):S7.
64. Alomar MJ, Hourani AA, Sulaiman SA. Proposal for the development of adverse drug reaction prediction model. Am J Pharmacol Toxicol 2008, 3:193-200.
65. Roth B, Lopez E, Patel S, Kroeze W. The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches? Neuroscientist 2000, 6:262.
66. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucleic Acids Res 2000, 28:235-242.
67. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, Katayama T, Araki M, Hirakawa M. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006, 34:D354-D357.
68. Joshi-Tope G, Gillespie M, Vastrik I, D'Eustachio P, Schmidt E, de Bono B, Jassal B, Gopinath GR, Wu GR, Matthews L, et al. Reactome: a knowledgebase of biological pathways. Nucleic Acids Res 2005, 33: D428-D432.
69. Pathway Interaction Database. Available at: http://pid.nci.nih.gov. (Accessed October 7, 2010).
70. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z,Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006, 34:D668-D672.
71. Gunther S, Kuhn M, Dunkel M, Campillos M, Senger C, Petsalaki E, Ahmed J, Urdiales EG, Gewiess A, Jensen LJ, et al. SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res 2008, 36:D919-D922.
72. Okuno Y, Yang J, Taneishi K, Yabuuchi H, Tsujimoto G. GLIDA: GPCR-ligand database for chemical genomic drug discovery. Nucleic Acids Res 2006, 34:D673-D677.
73. Gong L, Owen RP, Gor W, Altman RB, Klein TE. PharmGKB: an integrated resource of pharmacogenomic data and knowledge. Curr Protoc Bioinformatics 2008, Chapter 14(Unit 14):17.
74. Hewett M, Oliver DE, Rubin DL, Easton KL, Stuart JM, Altman RB, Klein TE. PharmGKB: the pharmacogenetics knowledge base. Nucleic Acids Res 2002, 30:163-165.
75. Davis AP, Murphy CG, Saraceni-Richards CA, Rosenstein MC, Wiegers TC, et al. Comparative Toxicogenomics Database: a knowledgebase and discovery tool for chemical-gene-disease networks. Nucleic Acids Res 2009, 37:D786-D792.
76. Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. BindingDB: a web-accessible database of experimentally determined protein-ligand binding afinities. Nucleic Acids Res 2007, 35:D198-D201.
77. Kuhn M, Szklarczyk D, Franceschini A, Campillos M, von MeringC, Jensen LJ, Beyer A, Bork P. STITCH 2: an interaction network database for small molecules and proteins. Nucleic Acids Res 2010, 38:D552-D556.
78. Lee S, Park K, Dongsup K. Building a drug-target network and its applications. Exp Opin Drug Discov 2009, 4:1177-1189.
79. Chautard E, Thierry-Mieg N, Ricard-Blum S. Interaction networks: from protein functions to drug discovery. A review. Pathol Biol (Paris) 2009, 57:324-333.
80. Kuhn M, Campillos M, Letunic I, Jensen LJ, Bork P. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 2010, 6:343.
81. Frijters R, Verhoeven S, Alkema W, van Schaik R, Polman J. Literature-based compound profiling: application to toxicogenomics. Pharmacogenomics 2007, 8:1521-1534.
82. Norén GN, Edwards IR. Modern methods of pharmacovigilance: detecting adverse effects of drugs. Clin Med 2009, 9:486-489.
83. Härmark L, van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol 2008, 64:743-752.
84. Watterson C, Lanevschi A, Horner J, Louden C. A comparative analysis of acute-phase proteins as inflammatory biomarkers in preclinical toxicology studies: implications for preclinical to clinical translation. Toxicol Pathol 2009, 37:28-33.
85. Ridings JE, Barratt MD, Cary R, Earnshaw CG, Eggington CE, Ellis MK, Judson PN, Langowski JJ, Marchant CA, Payne MP. Computer prediction of possible toxic action from chemical structure: an update on the DEREK system. Toxicology 1996, 106:267-279.
86. Cash GG. Prediction of the genotoxicity of aromatic and heteroaromatic amines using electrotopological state indices. Mutat Res 2001, 491:31-37.
87. Reese G. Cloud Application Architectures: Building Applications and Infrastructure in the Cloud: Transactional Systems for EC2 and eyond. Cambridge, MA: O'Reilly Media; 2009.
88. Srinivasan P. Generating hypotheses from MEDLINE. J Am Soc Inf Sci Technol 2004, 55:396-413.